As for the use of IL-12/IL-23 inhibitors in the treatment of PsA, a prospective randomized-controlled open-label study concluded that they could outperform TNF inhibitor treatment in terms of enthesitis remission rate [32]. The gene discussed is IL37; the disease is enthesitis.